These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29983382)

  • 21. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
    Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
    Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
    Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Song MK; Chung JS; Shin DH; Seol YM; Shin HJ; Choi YJ; Cho GJ
    Leuk Lymphoma; 2009 Jan; 50(1):54-61. PubMed ID: 19152170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].
    Zhan J; Yang SJ; Zhang W; Zhou DB; Zhang Y; Wang W; Wei C
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):41-47. PubMed ID: 35231992
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
    Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
    Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
    Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
    Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
    Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
    J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic significance of proteins expression by immunohistochemical method in diffuse large B cell lymphoma].
    Yu WJ; Cao LH; Wang JH; Wang ZM; Qian WB; Tong HY; Meng HT; Mai WY; Mao LP; Qian JJ; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):784-788. PubMed ID: 29081196
    [No Abstract]   [Full Text] [Related]  

  • 35. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2.
    Roh J; Cho H; Yoon DH; Hong JY; Lee AN; Eom HS; Lee H; Park WS; Han JH; Jeong SH; Park JS; Pak HK; Kim SW; Kim SY; Suh C; Huh J; Park CS
    Sci Rep; 2020 Jun; 10(1):10680. PubMed ID: 32606309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
    Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy.
    Curran KM; Schaffer PA; Frank CB; Lana SE; Hamil LE; Burton JH; Labadie J; Ehrhart EJ; Avery PR
    Vet Comp Oncol; 2017 Dec; 15(4):1269-1279. PubMed ID: 27514648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
    Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
    Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.